



16 December 2019

ASX Announcement

Race Receives \$159k R&D Tax Incentive Refund

16 December 2019: Race Oncology Limited ("RAC") is pleased to announce that the Company has received a \$159,371 R&D Tax Incentive refund for the 2018/2019 financial year.

The R&D Tax Incentive is an important Australian Government Program that refunds up to 43.5% of eligible expenditure on research and development.

- ENDS -

About Race Oncology (RAC: ASX)

Race Oncology is a specialty pharmaceutical company whose business model is to pursue later-stage drugs in the cancer field that have been overlooked by big pharma. The company's first drug is Bisantrene, a chemotherapy agent that was the subject of more than 40 clinical studies during the 1980s and 1990s before the drug was abandoned. Bisantrene has compelling clinical data in acute myeloid leukaemia (AML) as well as other cancers including breast and ovarian. Race is seeking to gain US FDA approval for Bisantrene. Bisantrene is the subject of three recently granted US patents owned by Race and has been awarded US Orphan Drug designation and a 'Rare Paediatric Disease' (RPD) designation that entitles Race to a valuable Priority Review Voucher (PRV) upon approval.

Release authorised by:

Peter Molloy, Managing Director
plmolloy@raceoncology.com

Media contact:

Heidi Cuthbert
+61 411 272 366
heidi.cuthbert@multiplier.com.au